通过患者报告结局指标比较局限性前列腺癌新型治疗模式的疗效
前瞻性队列纳入18家西班牙医院572例临床局限性前列腺癌患者(50-75岁,T1-T2,低危含T1c Gleason 3+4),随访24个月,用EPIC-26和SF-36v2电话访谈比较主动监测、机器人辅助根治性前列腺切除术(RARP)、调强放疗(IMRT)和实时近距离放疗。24个月PROMs完成率95.0%,主动监测副作用最少但性功能和躯体健康显著下降、心理健康中度改善;RARP尿失禁更重,IMRT和实时近距离放疗肠道症状更差。
要点
- 主动监测副作用最少,但24个月时性功能和躯体健康显著下降、心理健康中度改善。
- 与主动监测相比,RARP尿失禁更重,IMRT和实时近距离放疗肠道症状更差。
- 多数副作用似限于短期下降,但RARP的中重度尿失禁和IMRT或实时近距离放疗的中度肠道恶化持续存在。
核心结论
- 多数新型治疗模式的副作用似乎仅限于短期下降,但RARP患者存在中重度尿失禁、IMRT或实时近距离放疗患者存在中度肠道恶化。
- 主动监测、IMRT和实时近距离放疗患者心理健康呈中度改善。
研究设计与样本
- 前瞻性队列纳入18家西班牙医院572例临床局限性前列腺癌男性(50-75岁,T1-T2,低危含T1c Gleason 3+4),随访至24个月。
- 治疗决策由患者和医生共同做出,采用EPIC-26和SF-36v2在治疗前及治疗后3、6、12、24个月电话访谈,构建广义估计方程模型并以倾向评分加权处理治疗选择偏倚。
主要发现
- 24个月时PROMs完成率为95.0%。
- 主动监测副作用最少,但24个月时性功能下降0.4个标准差(p<0.001)、躯体健康下降0.5个标准差(p<0.001)、心理健康改善0.4个标准差(p=0.001)。
- 与主动监测相比,RARP尿失禁更重(p=0.030),IMRT和实时近距离放疗肠道症状更差(分别为p=0.027和p=0.007),均于24个月评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is scarce comparative effectiveness research on the new treatment modalities for localized prostate cancer. We aim to compare through Patient-Reported Outcome Measures (PROMs) the impact of active surveillance, robot-assisted radical prostatectomy (RARP), intensity-modulated radiotherapy (IMRT), and real-time brachytherapy, considering side effects (incontinence, irritative/obstructive urinary symptoms, sexual dysfunction and bowel symptoms) and physical and mental health. MATERIALS AND METHODS: Prospective cohort of men diagnosed with clinically localized prostate cancer (age 50-75y, T1-T2, and low risk including Gleason 3 + 4 in T1c) from 18 Spanish hospitals, followed up to 24 months. Treatment decisions were jointly made by patients and physicians (n = 572). The Expanded Prostate cancer Index Composite (EPIC-26) and Short-Form 36 (SF-36v2) were administered through telephone interviews before and three, six, 12, and 24 months after treatment. To account for correlation among repeated measures, generalized estimating equation models were constructed. All analyses were performed with propensity score weights to solve treatment selection bias. RESULTS: The PROMs completion rate at 24 months was 95.0 %. Active surveillance entails the fewest side effects, but with significant sexual (0.4 standard deviations [SD], p < 0.001) and physical health deterioration (0.5 SD, p < 0.001); and moderate mental health improvement (0.4 SD, p = 0.001) at 24 months. Compared with active surveillance, RARP presented greater urinary incontinence (p = 0.030), and IMRT and real-time brachytherapy worse bowel symptoms (p = 0.027 and p = 0.007) at 24 months. CONCLUSIONS: Most side effects of the new treatment modalities seem to be limited to short-term deteriorations, except for moderate-large urinary incontinence in patients who had undergone RARP and moderate bowel deterioration in patients treated with IMRT or with real-time brachytherapy. Furthermore, patients under active surveillance, IMRT, and real-time brachytherapy showed a moderate improvement in mental health.
引用
- Zamora V, Garin O, Suárez JF, et al. Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures. Clin Transl Radiat Oncol. 2023. PMID: 38021091. doi:10.1016/j.ctro.2023.100694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。